Matches in UGent Biblio for { <https://biblio.ugent.be/publication/593709#aggregation> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B172197.
- aggregation creator B172198.
- aggregation creator B172199.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 593709.bibtex.
- aggregation hasFormat 593709.csv.
- aggregation hasFormat 593709.dc.
- aggregation hasFormat 593709.didl.
- aggregation hasFormat 593709.doc.
- aggregation hasFormat 593709.json.
- aggregation hasFormat 593709.mets.
- aggregation hasFormat 593709.mods.
- aggregation hasFormat 593709.rdf.
- aggregation hasFormat 593709.ris.
- aggregation hasFormat 593709.txt.
- aggregation hasFormat 593709.xls.
- aggregation hasFormat 593709.yaml.
- aggregation isPartOf urn:issn:0903-1936.
- aggregation isPartOf urn:issn:1399-3003.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma".
- aggregation abstract "We compared the systemic and clinical effects of ciclesonide (CIC) and fluticasone propionate (FP), given on top of CIC 160 µg·day-1 and salmeterol 50 µg twice daily in 32 patients with persistent asthma using a randomized double-blind, placebo-controlled, double-dummy, five-period crossover design. All patients exhibited a PC20 methacholine <8 mg·ml-1 and a PC20 adenosine <60 mg·ml-1. Primary outcome was 24-h serum cortisol suppression after seven days. Secondary outcomes were changes in PC20 methacholine and adenosine after 9 days. FP 500 µg·day-1 and 1000 µg·day-1 significantly suppressed cortisol secretion versus placebo by –46.2 (95%C.I.: –83.8, –8.5) nmol·L-1 and by –76.1 (95%C.I.: –112.9, –39.3) nmol·L-1, respectively. Neither dose of CIC (320 or 640 µg·day-1) had a significant suppressive effect [–28.2 (95%C.I.: –65.5, +9.2) nmol·L-1 and – 37.3 (95%C.I.: –74.7, 0.0) nmol·L-1, respectively]; differences between FP 1000 µg·day-1 and both CIC treatments were statistically significant [for CIC 320 µg·day-1: –48.0 (95%C.I.: –84.8, –11.1) nmol·L-1; for CIC 640 µg·day-1: –38.8 (95%C.I.: –75.7, –1.9) nmol·L-1]. Compared with placebo, the increase in PC20 adenosine after the four treatments was small, but significant. Greater improvements in PC20 adenosine were seen with FP 500 µg·day-1 [1.8 (95%C.I.: 1.0, 2.6) doubling concentrations] compared with CIC 320 µg·day-1 [0.9 (95%C.I.: 0.1, 1.7) doubling concentrations]; no significant difference was seen between CIC 640 µg·day-1 and FP 1000 µg·day-1. For a similar decrease in hyperresponsiveness, cortisol secretion was suppressed significantly with moderate to high doses of FP, but not with CIC.".
- aggregation authorList BK423314.
- aggregation endPage "1286".
- aggregation issue "6".
- aggregation startPage "1277".
- aggregation volume "33".
- aggregation aggregates 722770.
- aggregation isDescribedBy 593709.
- aggregation similarTo 09031936.00079908.
- aggregation similarTo LU-593709.